IAH0968

SUNHO (China) BioPharmaceutical is running a Phase 2 trial of IAH0968, an afucosylated anti-HER2 monoclonal antibody engineered for enhanced antibody-dependent cellular cytotoxicity (ADCC), paired with CAPEOX chemotherapy (capecitabine plus oxaliplatin) for HER2-positive advanced gastric cancer and other HER2-expressing solid tumors [2]. The trial registration shows Phase 2 per ClinicalTrials.gov even though the protocol title reads 'Phase II/III' [2]. A first-in-human Phase Ia/Ib study published in Frontiers in Immunology (late 2024) reported a confirmed objective response rate (ORR) of 13.3% and disease control rate (DCR) of 53.3% in heavily pretreated HER2-positive solid tumors [1]. This is a crowded space - trastuzumab is generic, trastuzumab deruxtecan (Enhertu) just rewrote second-line HER2+ gastric cancer treatment, zanidatamab (Ziihera) won FDA accelerated approval as the first bispecific HER2 antibody in HER2+ biliary tract cancer in November 2024, and Chinese ADC disitamab vedotin already has domestic approval [5][8][9]. For a novel anti-HER2 antibody to matter commercially, it needs to show either a safety advantage over trastuzumab biosimilars or a clear efficacy gap - especially outside China, where the bar is set by Enhertu in HER2-positive disease [5]. Right now the public dataset is one early-phase paper with a sub-20% ORR in late-line patients; no Phase 2 readout has been disclosed.

IAH0968 is a novel investigational compound, never approved anywhere. Per ClinicalTrials.gov, NCT06504732 is registered as Phase 2 with planned enrollment of 90 patients in HER2-positive gastric cancer plus the CAPEOX backbone, despite the official title reading 'Phase II/III' [2]. The discrepancy is worth flagging: protocols labeled II/III sometimes claim a seamless adaptive design but often end up as Phase 2 trials with a planned expansion. The primary endpoint is the number of participants with at least one adverse event - a safety/tolerability readout, not an efficacy one [2]. That tells you this is closer to a dose-finding or safety expansion than a registration-enabling Phase 3. No FDA designations have been reported: no breakthrough therapy, no fast track, no orphan drug for this asset, and the sponsor's development plan looks China-centric. The published Phase Ia/Ib in heavily pretreated HER2-positive solid tumors gives a first look at single-agent safety, pharmacokinetics, and a preliminary ORR of 13.3% (DCR 53.3%) [1]. Expected Phase 2 readout: based on standard 12-18 month enrollment plus follow-up for a 90-patient Phase 2 starting recruitment in 2024, top-line safety could surface in 2027-H1, with efficacy follow-up later. No published interim analysis plan, no biomarker stratification details, and no out-licensing announcement have surfaced in public materials.

HER2 is a protein that sits on the surface of cells and acts like a 'grow now' signal - when a cell makes too much of it, the cell keeps dividing when it shouldn't. About 15-20% of stomach cancers and 15-20% of breast cancers overexpress HER2, which is why blocking HER2 has been one of the most reliable plays in oncology [4][5]. The target is well-validated: trastuzumab (a naked antibody) plus chemotherapy became standard for HER2-positive gastric cancer after the ToGA trial in 2010 [4]; trastuzumab deruxtecan (Enhertu, an antibody-drug conjugate - abbreviated ADC, meaning an antibody chemically linked to a cytotoxic payload that delivers chemotherapy directly to HER2-expressing cells via a topoisomerase inhibitor warhead) extended survival in second-line gastric cancer in DESTINY-Gastric01 [5]. Zanidatamab (Ziihera) is a bispecific HER2 antibody that engages two non-overlapping HER2 epitopes (ECD2/domain II plus ECD4/domain IV, vs. trastuzumab's domain IV only), driving receptor clustering and enhanced internalization; it received FDA accelerated approval in HER2+ biliary tract cancer in November 2024 based on a 52% ORR in HERIZON-BTC-01 [9] and is advancing in HER2+ gastric trials. IAH0968 is described in the Phase Ia/Ib publication as an afucosylated anti-HER2 monoclonal antibody - afucosylation strips fucose sugars from the antibody Fc region, increasing FcγRIIIa binding affinity on natural killer cells and amplifying antibody-dependent cellular cytotoxicity (ADCC) relative to standard trastuzumab [1]. That is a legitimate, if modest, mechanistic wedge: an ADCC-enhanced naked antibody could differentiate on innate-immune killing in tumors where T-DXd toxicity (interstitial lung disease) is a concern. The Song et al. paper does not publicly disclose the specific HER2 epitope IAH0968 binds, so head-to-head epitope differentiation vs. trastuzumab remains uncharacterized. Target validation is high; molecule-specific rationale (afucosylated ADCC) is real but narrow.

NCT06504732 is a Phase 2 trial sponsored by SUNHO BioPharmaceutical, recruiting 90 patients with HER2-positive gastric cancer or other HER2-expressing advanced solid tumors [2]. Treatment is IAH0968 plus CAPEOX - capecitabine (an oral 5-FU prodrug) plus oxaliplatin (a platinum chemotherapy), the standard frontline doublet for advanced gastric cancer. The primary endpoint is adverse event frequency, not response rate or progression-free survival [2]. That is the design choice you make for a safety expansion or combination tolerability study, not a registration-enabling efficacy trial. There is no published comparator arm in the registration; the design reads as single-arm open-label. Secondary endpoints, blinded review, and biomarker subgrouping details are not disclosed in the public CT.gov record. A few concrete concerns: (1) for HER2-positive gastric cancer, the global standard frontline is now trastuzumab plus chemo plus pembrolizumab after KEYNOTE-811, which showed median OS of 20.0 vs 16.8 months with the pembrolizumab combination [6] - running a HER2 antibody plus chemo alone may not reflect current best care; (2) a 90-patient safety primary will not establish efficacy at the level Western regulators require; (3) mixing HER2-expressing solid tumors with HER2-positive gastric cancer makes the population heterogeneous, which is fine for early signal-finding but complicates interpretation; (4) HER2 positivity definitions differ across markets - China typically accepts IHC 2+/FISH+ and IHC 3+, while the FDA-approved zanidatamab indication required IHC 3+ specifically [9] - a China-only dataset may not be portable to Western trials without re-enrolling under stricter biomarker criteria. Enrollment status is 'recruiting' as of the last update.

Our model estimates a 2% chance this drug is eventually approved. It starts from the historical base rate - about 13% for Phase 2 drugs in this area - then adjusts based on ten facts about the trial and sponsor. Larger-than-typical enrollment works in its favor, while the sponsor's thin or weak approval record, heavier-than-usual blinding, and few secondary endpoints pull the number down. The remaining factors fall close to average for this stage, so they leave the estimate near where the base rate started.

Five real failure modes. (1) Efficacy risk: the trial primary is safety, not efficacy [2]. Even a clean safety readout does not unlock a registration path. The published Phase Ia/Ib showed a confirmed ORR of 13.3% in heavily pretreated patients [1] - well below the ~47% ORR seen in the ToGA frontline trastuzumab arm [4] and the 51% ORR seen with Enhertu in DESTINY-Gastric01 [5], though late-line comparisons are imperfect. (2) Competitive risk: HER2-positive gastric is now a multi-product market. Frontline standard is trastuzumab plus chemo plus pembrolizumab after KEYNOTE-811 [6]; second-line is Enhertu [5]; Chinese patients also have disitamab vedotin [8]; and zanidatamab - the first bispecific HER2 antibody - is now FDA-approved in biliary tract and advancing in gastric [9]. A new naked anti-HER2 antibody needs to either replace trastuzumab on cost (biosimilars already do that) or beat one of the ADCs/bispecifics on efficacy. The afucosylated ADCC story is real but narrow. (3) Regulatory geography risk: SUNHO is China-based and the trial appears China-only [2]. Bringing a HER2 antibody through FDA approval against entrenched competitors would require Western data the sponsor has not announced. (4) On-target safety risk: HER2 inhibition carries known cardiac toxicity (decreased left ventricular ejection fraction) - manageable with trastuzumab but a real signal to watch in any new antibody, especially combined with platinum chemotherapy. (5) Differentiation risk: beyond afucosylation, public materials do not characterize IAH0968's epitope or binding mode, dosing schedule, or route relative to trastuzumab. Without a clear efficacy or convenience wedge, even a positive trial leaves the asset competing on price against generics.

Low signal for Western investors right now. SUNHO BioPharmaceutical is not a recognized name in US oncology and the development plan looks China-domestic, so this is not on the radar of US/EU biotech analysts. The data point that would change that: a published Phase 2 readout with confirmed ORR above 40% in HER2-positive gastric or biliary tract cancer, or any indication of out-licensing to a Western partner. Either would force a re-rate. The data point that shuts the file: enrollment slowdown reported in CT.gov updates, or a Phase 2 readout below 25% ORR (especially given the 13.3% Phase Ia/Ib signal in pretreated patients [1]). Worth checking back in mid-2027 when the Phase 2 (NCT06504732) is plausibly approaching primary completion [2]. In the meantime, the more interesting SUNHO asset to track may be IAP0971, a separate compound in Phase 1 (NCT06223841) [3] - if SUNHO has a pipeline strategy beyond a single HER2 me-better, that becomes the story. Right now the file is: validated target, crowded market (now including a first-in-class bispecific in zanidatamab), thin differentiation beyond afucosylation, China-only data. Keep it on a watchlist, not a workbench.